Jerry Lee
Showing 1–3 of 3 transcripts.
- Goldman Sachs30 min
Alnylam’s Yvonne Greenstreet on RNAi and a ‘golden era’ in biotech
Alnylam Pharmaceuticals leverages a decade of RNA interference research to achieve a 55% clinical success rate and recently secured approval for Amvutra to treat hereditary transthyretin-mediated amyloidosis. Under CEO Yvonne Greenstreet, the company aims to become a top-five biotech leader by 2026 through a five-year strategy to deliver 25 clinical programs and expand into common diseases like hypertension. To reach this goal, Alnylam integrates AI-driven drug design with a culture of diversity and patient advocacy to de-risk development and target tissues beyond the liver, including the central nervous system.
- Goldman Sachs19 min
How Angela Hwang helped lead Pfizer through the unknowns of Covid to deliver a vaccine
Angela Huang, Pfizer's Chief Commercial Officer, detailed the "Project BioSpeed" initiative that accelerated the development of the company's COVID-19 vaccine to approximately nine months through parallel development and a "fixed goal, flexible process" framework. Under her leadership, which spans 26,000 colleagues across 185 countries, the organization scaled annual manufacturing capacity from 200 million to over one billion doses while enforcing a mandatory 30% minority representation in clinical trials. The presentation highlighted how this crisis-driven collaboration required admitting uncertainty and failing fast without altering the final deadline, offering a model for translating high-stakes innovation into standard business operations.
- Goldman Sachs9 min
The Surge in Global Biotech Innovation
In 2020, the biotech sector raised $55 billion in equity financing and pursued approximately $50 billion in M&A activity despite an initial pandemic pause, driven by supply-side advancements in genomic medicine and the urgent need for external innovation. Leading pharmaceutical giants like Pfizer, BioNTech, and Moderna deployed significant capital to develop vaccine candidates with high efficacy, while large-cap companies utilized substantial dry powder to acquire novel therapeutic technologies ahead of anticipated patent cliffs. Concurrently, cross-border collaboration shifted toward deep R&D partnerships between U.S., European, and Chinese entities, marking the emergence of Chinese biotechs as potential global competitors supported by government initiatives and a wave of returning scientific talent.